Not yet recruitingPHASE1, PHASE2NCT06736080

Safety and Efficacy of Gene Therapy of FHL Type 3 Caused by Mutations in the Human UNC13D Gene by Transplantation of a Single Dose of Autologous CD34+ Cells Transduced Ex Vivo with the UNC13D LV Vector Expressing the UNC13D CDNA

Studying Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Assistance Publique - Hôpitaux de Paris
Principal Investigator
Jean-Sébastien DIANA, MD, PhD
Assitance publique - Hôpitaux de Paris
Intervention
MUNC-CD34(drug)
Enrollment
5 enrolled
Eligibility
17 years · All sexes
Timeline
20252029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06736080 on ClinicalTrials.gov

Other trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Additional recruiting or active studies for the same condition.

See all trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

← Back to all trials